REFERENCES
1. Ma T, Lu Y, Liu K, et al. Global, regional, and national burden of liver cancer attributable to high BMI, 1990-2021, with future projections to 2040. Front Oncol. 2025;15:1630875.
2. Li P, Ding Z, Feng Y, et al. Global, regional, and national burden of hepatocellular carcinoma and contribution of nine modifiable risk factors across 185 countries/territories in 2022. Sci Bull. 2026;71:838-49.
3. Mauro E, de Castro T, Zeitlhoefler M, et al. Hepatocellular carcinoma: epidemiology, diagnosis and treatment. JHEP Rep. 2025;7:101571.
4. Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023;20:524-37.
5. Pelizzaro F, Ferrarese A, Gambato M, et al. Hepatocellular carcinoma recurrence after liver transplantation: risk factors, targeted surveillance and management options. Hepatoma Res. 2024;10:44.
6. Zhang X, Zhao L, Campbell PT, et al. The impact of genetic and environmental risk factors on adverse liver outcomes. Int J Cancer. 2026;158:2317-28.
7. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.
8. Akinyemiju T, Abera S, Ahmed M, et al. ; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683-91.
9. Pu R, Liu W, Zhou X, et al. The effects and underlying mechanisms of hepatitis B virus X gene mutants on the development of hepatocellular carcinoma. Front Oncol. 2022;12:836517.
10. Chen JG, Kensler TW, Sun GJ, et al. Aflatoxin and liver cancer in China: the evolving research landscape. Toxins. 2026;18:61.
11. Tan J, Xing Z, Zu J, et al. Global burden of liver cancer mortality due to alcohol use from 1990 to 2021 and predictions to 2050. Hepatoma Res. 2026;12:31.
12. Tan J, Li Z, Shen Q, et al. Associations between physical activity and risk of liver cancer: results from a population-based cohort study in Chinese women. Hepatoma Res. 2024;10:1.
13. Zhou Y, Li Y, Zhou T, Zheng J, Li S, Li HB. Dietary natural products for prevention and treatment of liver cancer. Nutrients. 2016;8:156.
15. Ui A, Kuriyama S, Kakizaki M, et al. Green tea consumption and the risk of liver cancer in Japan: the Ohsaki Cohort study. Cancer Causes Control. 2009;20:1939-45.
16. Kim TL, Jeong GH, Yang JW, et al. Tea consumption and risk of cancer: an umbrella review and meta-analysis of observational studies. Adv Nutr. 2020;11:1437-52.
17. Feng X, Li R, Yan M, Yuan C, Wu Y. Alcohol and tea consumption in relation to liver cancer risk by diabetes status: a prospective cohort study of 0.5 million Chinese adults. Nutrients. 2025;17:2870.
18. Bamia C, Lagiou P, Jenab M, et al. Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: multicentre, prospective cohort study. Int J Cancer. 2015;136:1899-908.
19. IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25.
20. Gao S. Epidemiological study of primary liver cancer in urban Shanghai. Ph.D. Dissertation, Fudan University, 2011. (in Chinese) Available from https://kns.cnki.net/kcms2/article/abstract?v=tQWh-SbE9Gpp101axFGWPn2dvLsbbwqd-KLiAsHLY-uswmYpCWNn3T_fOBoJ0qwCN0gBHDTihNdcrDAgTTx6_bQrpmTDNZlY90_Q5gqTrWR5GdmRqAbyuEISsYz_VHZ6TZLAX5vIJmUErL_b0dzUvXCC2dkTVi4rsGEZ3GrJp_bs8FXujhix_H9FhNrQNJrT_nObPgabg2o&uniplatform=NZKPT&captchaId=5da905f0-da7f-41da-b273-8e80d2d56fd5 [accessed 24 September 2026].
21. Nagano J, Kono S, Preston DL, Mabuchi K. A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan). Cancer Causes Control. 2001;12:501-8.
22. Inoue M, Kurahashi N, Iwasaki M, et al. ; Japan Public Health Center-Based Prospective Study Group. Effect of coffee and green tea consumption on the risk of liver cancer: cohort analysis by hepatitis virus infection status. Cancer Epidemiol Biomarkers Prev. 2009;18:1746-53.
23. Li ZY, Tan YT, Liu DK, Gao LF, Li HL, Xiang YB. Cumulative consumption of tea is associated with lower risk of liver cancer: updated results from the Shanghai Women’s Health Study. Int J Cancer. 2023;152:1115-23.
24. Tamura T, Wada K, Konishi K, et al. Coffee, green tea, and caffeine intake and liver cancer risk: a prospective cohort study. Nutr Cancer. 2018;70:1210-6.
25. Butler LM, Huang JY, Wang R, et al. Urinary biomarkers of catechins and risk of hepatocellular carcinoma in the Shanghai Cohort Study. Am J Epidemiol. 2015;181:397-405.
26. Duan JX, Zhang JB. A case-control study on pathogenic factors of primary liver cancer in Dianjiang County, Chongqing. Southwest Military Doctor. 2018;20:545-9. (in Chinese) Available from https://kns.cnki.net/kcms2/article/abstract?v=tQWh-SbE9GrqrCtd7dh4WfdC-LOAMbQEq2Wk5yIP-DAY1cnLGdoM5fn0r4K2GaqSRzWzf5SXmb0ZnUOeI-RgpYmwfkLJ6JZFPLrpVFUUNTQ_0G4dD4_w9oJVvGkx2mTlcfMu6KWmsZojCpS16TL0bgPmomLPdUD6-CRNpVJMEAuRi8kmVQJDcGoHDJlqKdIOht2NJpfNGqI&uniplatform=NZKPT&captchaId=abf3a8fb-a380-4a99-8468-446692f7e737 [accessed 24 September 2026].
27. Lin ZB, Qi YF, Zhou XF, et al. Risk factors for primary liver cancer in Shunde District, Guangdong. Chin J Dis Control Prev. 2017;21:993-6. (in Chinese).
28. Song SF, Shen JC, Lin GZ, et al. Matched case-control study on risk factors for primary liver cancer in Guangzhou. South China J Prev Med. 2014;40:517-20. (in Chinese).
29. Liu X, Baecker A, Wu M, et al. Tea consumption and liver cancer: a population-based case-control study in eastern China. Nutrients. 2025;17:2647.
30. Li Y, Chang SC, Goldstein BY, et al. Green tea consumption, inflammation and the risk of primary hepatocellular carcinoma in a Chinese population. Cancer Epidemiol. 2011;35:362-8.
31. Montella M, Polesel J, La Vecchia C, et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer. 2007;120:1555-9.
32. Zhao LG, Li ZY, Feng GS, et al. Tea drinking and risk of cancer incidence: a meta-analysis of prospective cohort studies and evidence evaluation. Adv Nutr. 2021;12:402-12.
33. Li M, Duan Y, Wang Y, Chen L, Abdelrahim MEA, Yan J. The effect of green tea consumption on body mass index, lipoprotein, liver enzymes, and liver cancer: an updated systemic review incorporating a meta-analysis. Crit Rev Food Sci Nutr. 2024;64:1043-51.
34. Bravi F, La Vecchia C, Turati F. Green tea and liver cancer. Hepatobiliary Surg Nutr. 2017;6:127-9.
35. Zhao T, Li C, Wang S, Song X. Green tea (Camellia sinensis): a review of its phytochemistry, pharmacology, and toxicology. Molecules. 2022;27:3909.
36. Capasso L, De Masi L, Sirignano C, et al. Epigallocatechin gallate (EGCG): pharmacological properties, biological activities and therapeutic potential. Molecules. 2025;30:654.
37. Farhan M. Green tea catechins: nature’s way of preventing and treating cancer. Int J Mol Sci. 2022;23:10713.
38. Goleij P, Heidari MM, Motevalli H, et al. Targeting the HGF/MET axis in cancer: therapeutic promise for natural compounds. Eur J Med Chem. 2025;298:118027.
39. Alam M, Gulzar M, Akhtar MS, et al. Epigallocatechin-3-gallate therapeutic potential in human diseases: molecular mechanisms and clinical studies. Mol Biomed. 2024;5:73.
40. Alam M, Ali S, Ashraf GM, Bilgrami AL, Yadav DK, Hassan MI. Epigallocatechin 3-gallate: from green tea to cancer therapeutics. Food Chem. 2022;379:132135.
41. Li S, Yin S, Ding H, et al. Polyphenols as potential metabolism mechanisms regulators in liver protection and liver cancer prevention. Cell Prolif. 2023;56:e13346.
42. Niu C, Zhang J, Okolo PI 3rd. Liver cancer wars: plant-derived polyphenols strike back. Med Oncol. 2024;41:116.
43. Hayashi A, Terasaka S, Nukada Y, et al. 4”-Sulfation is the major metabolic pathway of epigallocatechin-3-gallate in humans: characterization of metabolites, enzymatic analysis, and pharmacokinetic profiling. J Agric Food Chem. 2022;70:8264-73.
44. Scholl C, Lepper A, Lehr T, et al. Population nutrikinetics of green tea extract. PLoS One. 2018;13:e0193074.
45. Sasaki GY, Vodovotz Y, Yu Z, Bruno RS. Catechin bioavailability following consumption of a green tea extract confection is reduced in obese persons without affecting gut microbial-derived valerolactones. Antioxidants. 2022;11:2490.
46. Hodges JK, Sasaki GY, Vodovotz Y, Bruno RS. Gallation and B-Ring dihydroxylation increase green tea catechin residence time in plasma by differentially affecting tissue-specific trafficking: compartmental model of catechin kinetics in healthy adults. Nutrients. 2023;15:4021.
47. Dos Reis Simpronio M, Machado ART, Santos P, Ribeiro DL, Antunes LMG, Aissa AF. Unraveling the effects of epigallocatechin-3-gallate on hepatocellular carcinoma cells: a comparative analysis of monolayer vs multicellular tumor spheroids. ACS Omega. 2025;10:34238-53.
48. EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS); Younes M, Aggett P, Aguilar F, et al. Scientific opinion on the safety of green tea catechins. EFSA J. 2018;16:e05239.
49. Teschke R, Xuan TD. Suspected herb induced liver injury by green tea extracts: critical review and case analysis applying RUCAM for causality assessment. Jap J Gastroenterol Hepatol. 2019;6:1-16. Available from https://jajgastrohepto.org/pdf/JJGH-v2-1030.pdf [accessed 24 September 2026].
50. Teschke R, Schulze J. Green tea and the question of reduced liver cancer risk: the dawn of potential clinical relevance? Hepatobiliary Surg Nutr 2017;6:122-6.
